1887
Volume 2022, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Omalizumab (XOLAIR®) is a recombinant DNA-derived humanized IgG1κ monoclonal antibody that binds to IgE and was first introduced in Qatar in 2009. Omalizumab is used to treat moderate-to-severe allergic asthma (SAA), chronic idiopathic urticaria (CIU), and chronic rhinosinusitis with nasal polyposis (CRSwNP). In this study, we have described a proposal to investigate the outcomes and impact of the clinical use of omalizumab for the labeled indications (SAA, CIU, and CRSwNP) and other off-label indications (food allergy, dermatitis, and others) in clinical practice in Qatar. This is a mixed-design study in which the first stage included a chart review of all the patients from the Allergy and Immunology Division registry who received omalizumab since May 2009. The second stage was a cross-sectional questionnaire to review all (previous and current) patients and identify their current health status and treatment outcomes. The third stage was a proof of concept and consisted of selecting a cohort to investigate the omalizumab mechanism for patients before and after administration. Patients with a physician diagnosis of asthma and/or urticaria fulfilling the diagnostic criteria for omalizumab administration and patients with off-label indications were recruited. Expected outcomes included identifying the real-life effectiveness and the experience of using omalizumab in Qatar and reporting all potential adverse effects that might have been missed during early trials or other published studies. This study was essential to observe Qatar’s local clinical practice regarding the use of omalizumab; and in addition, we could gather data about the risk factors contributing to disease recovery or progression and those resulting in favorable or unfavorable outcomes. We expect the results to augment the current knowledge about understanding diseases and the global experience on the use of omalizumab.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2022.fqac.3
2022-03-28
2022-09-28
Loading full text...

Full text loading...

References

  1. Niven RM, Saralaya D, Chaudhuri R, Masoli M, Clifton I, et al. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). BMJ Open. 2016 Aug 9; 6:(8):e011857. doi: 10.1136/bmjopen-2016-011857..
    [Google Scholar]
  2. CBER Approval Letter, XOLAIR (Omalizumab) [Internet]. U.S. Food and Drug Administration; 2013 [cited 2022 Jan 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/omalgen062003L.htm..
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2022.fqac.3
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error